There are two main reasons for including NTA-tau in the biofluid staging scheme: first, NTA-tau is measurable in CSF and blood [18, 19, 33] and second, NTA-tau increases during mid-to-late AD stages, is strongly associated with tau pathology, and can track tau deposition in AD [18, 19, 41]. This evidence concerns the gene MAPT and Alzheimer disease.